Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Health Care Equipment2.92%-0.42 ppManaged Health Care1.87%-0.41 ppBiotechnology2.28%-0.34 ppLife Sciences Tools & Services1.64%-0.21 ppPharmaceuticals5.03%-0.19 ppHealth Care Distributors0.44%+0.05 ppHealth Care Services0.68%-0.03 ppHealth Care Facilities0.24%-0.03 ppHealth Care Supplies0.19%-0.00 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.28%
Industry change · 12M
-0.34 pp
Biotechnology · contribution
-0.335 pp
Company participation
13%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Apr 2024 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Gilead Sciences → GILD | United States | $81.2bn | 0.235% | -0.055 pp | -0.111 pp | -17.6% | No |
| AbbVie → ABBV | United States | $287.3bn | 0.832% | -0.031 pp | -0.071 pp | +12.0% | No |
| Biogen → BIIB | United States | $31.3bn | 0.091% | -0.016 pp | -0.058 pp | -29.4% | No |
| Moderna → MRNA | United States | $42.1bn | 0.122% | +0.008 pp | -0.051 pp | -17.0% | Yes |
| Incyte → INCY | United States | $11.7bn | 0.034% | -0.005 pp | -0.022 pp | -30.0% | No |
| Regeneron Pharmaceuticals → REGN | United States | $83.7bn | 0.242% | -0.021 pp | -0.012 pp | +11.1% | No |
| Amgen → AMGN | United States | $146.8bn | 0.425% | -0.075 pp | -0.007 pp | +18.1% | No |
| Vertex Pharmaceuticals → VRTX | United States | $101.5bn | 0.294% | -0.038 pp | -0.002 pp | +15.3% | No |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.